Research Findings
Recent Research including DCRP clinicians.Click on study title link to view abstract (appears in new window)
Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine.
Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, Worthington J, Baer L, Rosenbaum JF.
Body dysmorphic disorder in outpatients with major depression.
Nierenberg AA, Phillips KA, Petersen TJ, Kelly KE, Alpert JE, Worthington JJ, Tedlow JR, Rosenbaum JF, Fava M.
Treatment Approaches to Major Depressive Disorder Relapse. part 2: reinitiation of antidepressant treatment.
Fava M, Schmidt ME, Zhang S, Gonzales J, Raute NJ, Judge R.
Treatment Approaches to Major Depressive Disorder Relapse. part 1: dose increase.
Schmidt ME, Fava M, Zhang S, Gonzales J, Raute NJ, Judge R.
Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression.
Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA, Fava M.
Early drop-outs, late drop-outs and completers: differences in the continuation phase of a clinical trial. Sonawalla SB, Farabaugh AH, Leslie VM, Pava JA, Matthews JD, Fava M.
Early drop-outs, late drop-outs and completers: differences in the continuation phase of a clinical trial. Sonawalla SB, Farabaugh AH, Leslie VM, Pava JA, Matthews JD, Fava M.
Sexual functioning and SSRIs. Fava M, Rankin M.
Predictors of stable personality disorder diagnoses in outpatients with remitted depression. Farabaugh A, Mischoulon D, Yeung A, Alpert J, Matthews J, Pava J, Fava M. J.
T3 blood levels and treatment outcome in depression. Iosifescu DV, Howarth S, Alpert JE, Nierenberg AA, Worthington JJ, Fava M.
Screening for major depression in Asian-Americans: a comparison of the Beck and the Chinese Depression Inventory. Yeung A, Neault N, Sonawalla S, Howarth S, Fava M, Nierenberg AA.
Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. Fava M, Hoog SL, Judge RA, Kopp JB, Nilsson ME, Gonzales JS.
Use of the Chinese version of the Beck Depression Inventory for screening depression in primary care.Yeung A, Howarth S, Chan R, Sonawalla S, Nierenberg AA, Fava M.
A survey of prescribing practices in the treatment of depression. Petersen T, Dording C, Neault NB, Kornbluh R, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M.
NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients. Petersen T, Papakostas GI, Bottonari K, Iacoviello B, Alpert JE, Fava M, Nierenberg AA.
Fluoxetine treatment of depressed patients with comorbid anxiety disorders. Sonawalla SB. Farabaugh A. Johnson MW. Morray M. Delgado ML. Pingol MG. Rosenbaum JF. Fava M.
Melancholia and axis II comorbidity. Tedlow J. Smith M. Neault N. Polania L. Alpert J. Nierenberg A. Fava M.
Personality disorders and depression. Fava M. Farabaugh AH. Sickinger AH. Wright E. Alpert JE.
Treatment-Resistant Depression and Axis II Comorbidity. Petersen T. Hughes M. Papakostas GI. Kant A. Fava M. Rosenbaum JF.Nierenberg AA.
Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Sonawalla SB. Papakostas GI. Petersen TJ. Yeung AS. Smith MM. Sickinger AH. Gordon J. Israel JA. Tedlow JR. Lamon Fava S. Fava M.
Eating disorder symptomatology in major depression. Fava, M., Abraham, M.E., Clancy-Colecchi, K., Pava, J.A., Matthews, J., & Rosenbaum, J.F.
Gender differences in Axis I comorbidity among depressed outpatients. Fava, M., Abraham, M.E., Alpert, J.E., Pava, J.A., & Rosenbaum, J.F.
Lithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants. Nierenberg A, Papakostas GI, Petersen T, Worthington JJ III, Tedlow J, Alpert JE, Fava M.
Nortriptyline for Treatment Resistant Depression. Nierenberg A, Papakostas GI, Petersen T, Worthington JJ III, Tedlow J, Alpert JE, Fava M.
Switching to bupropion in fluoxetine-refractory depression. Fava M, Papakostas GI, Petersen T, Mahal Y, Quitkin F, Stewart J, McGrath P.
Anemia and macrocytosis in the prediction of serum folate and B12, and outcome in major depression. Mischoulon D, Burger JK, Spillmann MK, Worthington JJ, Fava M, Alpert JE.
Management of major depression in the primary care setting. Mischoulon D, McColl R, Howarth S, Lagomasino IT, Alpert JE, Nierenberg AA, Fava M.
An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding. Mischoulon D, Dougherty DD, Bottonari KA, Gresham RL, Sonawalla SB, Fischman AJ, Fava M.
Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder. Papakostas GI, Iosifescu DV, Petersen T, Hamill SK, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M.
Patterns of Axis I comorbidity in early-onset versus late-onset major depressive disorder: Axis I Disorders. Alpert JE, Fava M, Uebelacker LA, Nierenberg AA, Pava JA, Worthington JJ III, Rosenbaum JF.
An Automated Registration Algorithm for Measuring MRI Subcortical Brain Structures. Iosifescu DV, Shenton ME, Warfield SK, Kikinis R, Dengler J, Jolesz FA and McCarley.
The Impact of Medical Comorbidity on Acute Treatment in Major Depressive Disorder. Iosifescu DV, Nierenberg AA, Alpert JE, Smith M, Bitran S, Dording C, Fava M.